Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05809908
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2023-03-30
Brief Title:
Tricaprilin Phase 3 ALTER-AD Alternative-Alzheimer Disease Study
Sponsor:
Cerecin
Organization:
Cerecin
Study Overview
Official Title:
A Phase III 26-Week Double-blind Randomised Placebo-controlled Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects with Mild to Moderately Severe Probable Alzheimer Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effects of tricaprilin 20 g twice a day on cognition activities of daily living resource utilisation safety and tolerability in subjects with mild to moderately severe probable AD
This is a randomised double-blind placebo-controlled parallel-group multi-centre design in up to 535 participants
This is a randomised double-blind placebo-controlled parallel-group multi-centre design in up to 535 participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None